| 88.105 -1.605 (-1.79%) | 09-04 13:52 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 108.14 | 1-year : | 126.31 |
| Resists | First : | 92.58 | Second : | 108.14 |
| Pivot price | 89.9 |
|||
| Supports | First : | 86.1  |
Second : | 82.08 |
| MAs | MA(5) : | 89.71 |
MA(20) : | 89.89 |
| MA(100) : | 74.11 |
MA(250) : | 70.09 |
|
| MACD | MACD : | 2.2 |
Signal : | 2.9 |
| %K %D | K(14,3) : | 31.6 |
D(3) : | 44.4 |
| RSI | RSI(14): 53.1 |
|||
| 52-week | High : | 92.58 | Low : | 54.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DXCM ] has closed above bottom band by 3.8%. Bollinger Bands are 62.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 91.05 - 91.49 | 91.49 - 91.95 |
| Low: | 88 - 88.46 | 88.46 - 88.94 |
| Close: | 88.97 - 89.7 | 89.7 - 90.44 |
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Fri, 04 Sep 2026
Empowered Funds LLC Buys New Shares in DexCom, Inc. $DXCM - InsuranceNewsNet
Thu, 03 Sep 2026
Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks - finance.yahoo.com
Tue, 01 Sep 2026
Dexcom Announces Upcoming Conference Presentation - Business Wire
Mon, 31 Aug 2026
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings And A Promising 3.63% Upside - DirectorsTalk Interviews
Thu, 27 Aug 2026
DexCom (NASDAQ: DXCM) officer may sell 2,565 shares on Aug. 27, 2026 - Stock Titan
Mon, 24 Aug 2026
Dexcom (NASDAQ: DXCM) chair sells 26,756 shares around $90 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 377 (M) |
| Shares Float | 376 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 106.3 (%) |
| Shares Short | 17,550 (K) |
| Shares Short P.Month | 18,110 (K) |
| EPS | 2.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.94 |
| Profit Margin | 20.1 % |
| Operating Margin | 24.3 % |
| Return on Assets (ttm) | 10.3 % |
| Return on Equity (ttm) | 38.4 % |
| Qtrly Rev. Growth | 13.1 % |
| Gross Profit (p.s.) | 8.21 |
| Sales Per Share | 13.17 |
| EBITDA (p.s.) | 3.7 |
| Qtrly Earnings Growth | 43.5 % |
| Operating Cash Flow | 1,750 (M) |
| Levered Free Cash Flow | 1,020 (M) |
| PE Ratio | 35.61 |
| PEG Ratio | 1.7 |
| Price to Book value | 12.65 |
| Price to Sales | 6.67 |
| Price to Cash Flow | 18.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|